BIO vs. WST: Bio-Rad Laboratories vs. West Pharmaceutical Services Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and West Pharmaceutical Services (WST) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bio-Rad Laboratories (BIO) at 39.45% and West Pharmaceutical Services (WST) at 18.81% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

West Pharmaceutical Services (WST) at 25.37% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bio-Rad Laboratories (BIO) at 3.18 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Bio-Rad Laboratories (BIO) at 0.18 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while West Pharmaceutical Services (WST) at 44.87 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while West Pharmaceutical Services (WST) at 9.40 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics